Other studies have suggested that SHP2 can also act as a negative regulator of inflammation, for example, SHP2 has been identified as a detrimental factor in inflammatory bowel disease (IBD), which disrupts the macrophage response to interleukin 10 (Xiao et al, 2019). Here, PTPN11 is linked to inflammatory bowel disease.